TODD STRATEGY GROUP

Lobbying for BIOGEN, INC. · Biotechnology Company.

Filing 4th Quarter - Report

4th Quarter (Oct 1 - Dec 31) 2025 · District of Columbia · House · Senate · $50,000.00 income · posted Jan 20, 2026

Lobbying activity 2

Medicare/Medicaid

Alzheimer's Disease. Medicare Reimbursement for Prescription Drugs. Screening and Diagnosis, PET scan coverage and reimbursement and dementia care. 340B Program. PPRV (Pediatric Priority Review Voucher) program.

Health Issues

Drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements. Implementation of Inflation Reduction Act of 2022. Issues related to maternal health. 340B Program.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.